KRAS-targeted therapy shows promising first results in NSCLC

Until now KRAS-positive lung cancers have been considered ‘undruggable’ but early results with the first targeted therapy have shown promising and durable response rates. Presented at the World Congress on Lung Cancer 2019 meeting in Barcelona, the phase 1 study results...

Until now KRAS-positive lung cancers have been considered ‘undruggable’ but early results with the first targeted therapy have shown promising...

Research

‘Serious concerns’ about low standards of evidence for cancer drug approvals

The quality of clinical trials for new cancer therapies leaves room for improvement, according to an article in the latest BMJ. An analysis of 54 pivotal studies, which led to the European Medicines Agency (EMA) approval of 32 new cancer...

The quality of clinical trials for new cancer therapies leaves room for improvement, according to an article in the latest...

Lenvatinib/pembrolizumab combo approved for endometrial cancer

The US Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA), and Health Canada (HC) have simultaneously approved a two-drug combination for the treatment of advanced endometrial carcinoma. The three agencies worked together under the umbrella of Project Orbis, an...

The US Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA), and Health Canada (HC) have simultaneously approved...

Research

The furry pet effect in cancer patients: affection trumps infection risk

For cancer patients, pets have a positive effect on wellbeing that probably outweighs any risk even in immunocompromised patients, a new review suggests. That’s probably just as well...

For cancer patients, pets have a positive...